A detailed history of Squarepoint Ops LLC transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Squarepoint Ops LLC holds 32,862 shares of JANX stock, worth $1.79 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
32,862
Previous 43,151 23.84%
Holding current value
$1.79 Million
Previous $1.62 Million 15.27%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$35.12 - $64.78 $361,349 - $666,521
-10,289 Reduced 23.84%
32,862 $1.38 Million
Q1 2024

May 15, 2024

SELL
$7.93 - $49.75 $142,874 - $896,345
-18,017 Reduced 29.45%
43,151 $1.62 Million
Q4 2023

Feb 14, 2024

BUY
$5.85 - $11.7 $195,319 - $390,639
33,388 Added 120.19%
61,168 $656,000
Q2 2023

Aug 14, 2023

BUY
$11.08 - $15.92 $161,912 - $232,638
14,613 Added 110.98%
27,780 $329,000
Q1 2023

May 15, 2023

BUY
$11.25 - $22.21 $148,128 - $292,439
13,167 New
13,167 $159,000

Others Institutions Holding JANX

About Janux Therapeutics, Inc.


  • Ticker JANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,663,000
  • Market Cap $2.27B
  • Description
  • Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...
More about JANX
Track This Portfolio

Track Squarepoint Ops LLC Portfolio

Follow Squarepoint Ops LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

News

Stay updated on Squarepoint Ops LLC with notifications on news.